104 results
8-K
EX-99.1
STRO
Sutro Biopharma Inc
13 May 24
Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones
4:30pm
release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995
8-K
STRO
Sutro Biopharma Inc
2 Apr 24
Entry into a Material Definitive Agreement
5:10pm
harbor” provisions of the Private Securities Litigation Reform Act of 1995, and other federal securities laws. Any statements contained herein that do
8-K
EX-1.1
STRO
Sutro Biopharma Inc
2 Apr 24
Entry into a Material Definitive Agreement
5:10pm
Laws or Regulatory Authorizations and has no knowledge that the Applicable Regulatory Authorities is considering any such claim, litigation, arbitration
424B5
btl62wbr5ej5fvy0m
2 Apr 24
Prospectus supplement for primary offering
4:58pm
8-K
EX-99.1
rqfeaom
2 Apr 24
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
6:04am
8-K
inw0vwxnnf3
2 Apr 24
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
6:04am
8-K
EX-99.1
x89tnnl zd
25 Mar 24
Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones
4:30pm
8-K
EX-1.1
11kcp69ghk1m1eq00m
9 Feb 24
Other Events
4:27pm
424B5
qhgyl478
9 Feb 24
Prospectus supplement for primary offering
4:25pm
8-K
7yfn76 4bdji4dnqfe3g
8 Jan 24
Results of Operations and Financial Condition
7:31am
8-K
EX-99.1
a1stazxy n8hz6m
21 Nov 23
Departure of Directors or Certain Officers
4:05pm
8-K
EX-99.1
oxlm1owva1372sp1z
13 Nov 23
Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
4:30pm